These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29357804)

  • 41. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker.
    Filntisi A; Vlachakis D; Matsopoulos GK; Kossida S
    Cancer Inform; 2014; 13():179-86. PubMed ID: 25506200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted drug delivery using immunoconjugates: principles and applications.
    Pasquetto MV; Vecchia L; Covini D; Digilio R; Scotti C
    J Immunother; 2011; 34(9):611-28. PubMed ID: 21989410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Consortia-Various Structural and Synthetic Concepts for More Effective Therapeutics Synthesis.
    Pawełczyk A; Sowa-Kasprzak K; Olender D; Zaprutko L
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies.
    Lau J; Lee H; Rousseau J; Bénard F; Lin KS
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
    Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
    Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.
    Antczak C; Jaggi JS; LeFave CV; Curcio MJ; McDevitt MR; Scheinberg DA
    Bioconjug Chem; 2006; 17(6):1551-60. PubMed ID: 17105236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of tissue plasminogen activator specific "on demand cleavable" (odc) linkers for radioimmunotherapy by screening one-bead-one-compound combinatorial peptide libraries.
    Kumaresan PR; Natarajan A; Song A; Wang X; Liu R; DeNardo G; DeNardo S; Lam KS
    Bioconjug Chem; 2007; 18(1):175-82. PubMed ID: 17226971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells.
    Lim SH; Jeong YI; Moon KS; Ryu HH; Jin YH; Jin SG; Jung TY; Kim IY; Kang SS; Jung S
    Int J Pharm; 2010 Mar; 387(1-2):209-14. PubMed ID: 19945519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peptide-Drug Conjugate: A Novel Drug Design Approach.
    Ma L; Wang C; He Z; Cheng B; Zheng L; Huang K
    Curr Med Chem; 2017; 24(31):3373-3396. PubMed ID: 28393694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A periodate-cleavable linker for functional proteomics under slightly acidic conditions: application for the analysis of intracellular aspartic proteases.
    Maurer A; Zeyher C; Amin B; Kalbacher H
    J Proteome Res; 2013 Jan; 12(1):199-207. PubMed ID: 23176076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of ketone-oxime method for developing therapeutic on-demand cleavable immunoconjugates.
    Kumaresan PR; Luo J; Song A; Marik J; Lam KS
    Bioconjug Chem; 2008 Jun; 19(6):1313-8. PubMed ID: 18494516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of linker flexibility and length on the functionality of a cytotoxic engineered antibody fragment.
    Klement M; Liu C; Loo BL; Choo AB; Ow DS; Lee DY
    J Biotechnol; 2015 Apr; 199():90-7. PubMed ID: 25697559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel peptide linkers for highly potent antibody-auristatin conjugate.
    Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
    Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis of two new enrichable and MS-cleavable cross-linkers to define protein-protein interactions by mass spectrometry.
    Burke AM; Kandur W; Novitsky EJ; Kaake RM; Yu C; Kao A; Vellucci D; Huang L; Rychnovsky SD
    Org Biomol Chem; 2015 May; 13(17):5030-7. PubMed ID: 25823605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake.
    Schneider EL; Hearn BR; Pfaff SJ; Fontaine SD; Reid R; Ashley GW; Grabulovski S; Strassberger V; Vogt L; Jung T; Santi DV
    Bioconjug Chem; 2016 Oct; 27(10):2534-2539. PubMed ID: 27657443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.
    Tibbitts J; Canter D; Graff R; Smith A; Khawli LA
    MAbs; 2016; 8(2):229-45. PubMed ID: 26636901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cleavable carbamate linkers for controlled protein delivery from hydrogels.
    Hammer N; Brandl FP; Kirchhof S; Goepferich AM
    J Control Release; 2014 Jun; 183():67-76. PubMed ID: 24680687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.